Pharmacotherapy of dysthymia: review and new findings

1998 ◽  
Vol 13 (4) ◽  
pp. 203-209 ◽  
Author(s):  
M Versiani ◽  
AE Nardi ◽  
I Figueira
Keyword(s):  
Monoamine Oxidase ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Response Rate ◽  
Term Treatment ◽  
Reversible Inhibitors ◽  
Benefit Ratio ◽  
New Findings ◽  
Long Term Treatment

SummaryOpen trials with tricyclics, classical monoamine oxidase inhibitors (MAOIs) or lithium in dysthymia yielded a response rate in 45% of subjects. A long-term treatment of dysthymia with 276 patients treated during 4 years with either moclobemide, tranylcypromine or a combination of amitryptiline plus chlordiazepoxide is described. After discontinuation there was a relapse rate of 89.1%. The controlled studies with tricyclics, MAOIs, reversible inhibitors of monoamine oxidase (RIMAs), specific serotonin reuptake inhibitor (SSRIs) or benzamides showed that drugs well-tolerated work better in dysthymia, due to the fact that the treatment must be long-term. Sertraline was studied vs placebo or imipramine in primary dysthymia. Moclobemide, imipramine and placebo were also studied in 315 patients. Mean doses were 650 mg/d of moclobemide and 203.2 mg/d of imipramine. Moclobemide and sertraline were both efficacious and well tolerated. In a long term treatment the clinician should assess the risk-benefit ratio. Dysthymic patients are very sensitive to unwanted effects and compliance is a serious issue.

Central and peripheral dopamine beta hydroxylase: Responses to long term treatment with monoamine oxidase inhibitors

1980 ◽  
Vol 19 (9) ◽  
pp. 877-881 ◽  
Author(s):  
Pauline Lerner ◽  
L.F. Major ◽  
P.S. Dendel ◽  
I.C. Campbell ◽  
D.L. Murphy
Keyword(s):  
Monoamine Oxidase ◽  
Term Treatment ◽  
Monoamine Oxidase Inhibitors ◽  
Dopamine Beta Hydroxylase ◽  
Long Term Treatment

scholarly journals Do antipsychotic drugs lose their efficacy for relapse prevention over time?

2017 ◽  
Vol 211 (3) ◽  
pp. 127-129 ◽  
Author(s):  
Stefan Leucht ◽  
John M. Davis
Keyword(s):  
Relapse Prevention ◽  
Antipsychotic Drugs ◽  
Meta Analysis ◽  
Term Treatment ◽  
First Episode ◽  
Brain Volume Loss ◽  
New Findings ◽  
Long Term Treatment ◽  
Long Term Follow Up

SummaryThere is a debate about long-term treatment of schizophrenia with antipsychotic drugs, with some experts suggesting that these drugs should be discontinued. In this issue, Takeuchi et al demonstrated by a meta-analysis of 11 trials that antipsychotic drugs maintained their efficacy for relapse prevention for 1 year, whereas patients on placebo kept getting worse. We consider these findings in the light of the current discussion about possible dose-related brain volume loss, supersensitivity psychosis, the high variability of results in long-term follow-up studies and recent approaches to discontinue antipsychotics in patients with a first-episode. The new findings speak in favour of continuing antipsychotics at the same dose, at least in patients whose condition is chronic, but the topic is complex.

Hypothalamic-Pituitary-Adrenocortical Axis Changes in the Rat after Long-Term Treatment with the Reversible Monoamine Oxidase-A Inhibitor Moclobemide

1994 ◽  
Vol 60 (5) ◽  
pp. 509-519 ◽  
Author(s):  
Johannes M.H.M. Reul ◽  
Marta S. Labeur ◽  
Dimitri E. Grigoriadis ◽  
Errol B. De Souza ◽  
Florian Holsboer
Keyword(s):  
Monoamine Oxidase ◽  
Term Treatment ◽  
Monoamine Oxidase A ◽  
Long Term Treatment

scholarly journals Safety of Repeated Administration of Parenteral Ketamine for Depression

2020 ◽  
Vol 13 (7) ◽  
pp. 151
Author(s):  
David Feifel ◽  
David Dadiomov ◽  
Kelly C. Lee
Keyword(s):  
Adverse Events ◽  
Bladder Dysfunction ◽  
Response Rate ◽  
Repeated Administration ◽  
Term Treatment ◽  
Psychotic Symptoms ◽  
Electronic Survey ◽  
Treatment Of Depression ◽  
Long Term Treatment

The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to individuals for depression, and extracted reported adverse events. The survey was sent to 69 providers, of which 36 responded (52% response rate); after eliminating those that were incomplete, 27 were included in the analysis. The providers in the analysis collectively reported treating 6630 patients with parenteral ketamine for depression, one-third of whom received more than 10 treatments. Only 0.7% of patients experienced an adverse effect that required discontinuation of ketamine. Psychological distress during the treatment was the most frequent cause. Other adverse events were extremely rare (such as bladder dysfunction (0.1%), cognitive decline (0.03%) and psychotic symptoms (0.03%)). Among the 20 published reports of repeated parenteral ketamine treatments, rates of significant adverse events resulting in discontinuation were low (1.2%). The rate of adverse effects reported in the survey and the published literature is low, and suggests that long-term treatment of depression with ketamine is reasonably safe.

Sign in / Sign up

Export Citation Format

Share Document